insights_auto
Varför har ZYME gått ned 3,12%?
Gå på djupetchevron_right
ZYME:NASDAQ
Zymeworks Inc
25,15 US$
arrow_downward
−3,12%(−0,81) 1 d
2 okt., 16:00:00 GMT−4 · USD
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för ZYME …
Öppen
26,18 US$
Högt
26,19 US$
Lågt
25,04 US$
Börsvärde
1,78 md
Genomsn. vol.
834,00 tn
Volym
0,00
52v högst
31,34 US$
52v lägst
16,00 US$
EPS
−2,01 US$
Beta
1,17
Utestående aktier
70,96 mn
Antal anställda
231
Öppen
26,18 US$
Högt
26,19 US$
Lågt
25,04 US$
Börsvärde
1,78 md
Genomsn. vol.
834,00 tn
Volym
0,00
52v högst
31,34 US$
52v lägst
16,00 US$
EPS
−2,01 US$
Beta
1,17
Utestående aktier
70,96 mn
Antal anställda
231
Nyheter och artiklar
Från webbkällor och nyhetspartner
Stock Traders Daily
·
för 8 timmar sedan
Liquidity Mapping Around (ZYME) Price Events
AD HOC NEWS
·
för 18 timmar sedan
Zymeworks stock fell 3.12 percent after Theravance deal closes
AD HOC NEWS
·
för 19 timmar sedan
Zymeworks stock falls 3.12 percent after Theravance deal announced. Continued
Profil
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
Om Zymeworks Inc
VdKenneth Galbraith
Anställda231
Grundades2003
HuvudkontorVancouver, British Columbia, Kanada
Sektor-
Webbplatszymeworks.com